Literature DB >> 8096102

Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors.

D W Ye1, J F Zheng, S X Qian, Y J Ma.   

Abstract

Expression of the ras and the c-erbB-2 oncogene products was investigated in 56 cases of human bladder transitional cell carcinoma and 6 samples of human normal bladder tissue using an immunohistochemical method. Thirty of the 56 cases of bladder tumor were found to be immunohistologically positive with the monoclonal anti-ras p21 antibody, while 19 of 56 cases were positive with the polyclonal anti-c-erbB-2 oncoprotein antibody. All 6 controls were negative with both antibodies. The ras p21 positive staining was found more frequently in the well or moderately differentiated, superficial and non-recurrent tumors than in the poorly differentiated (p < 0.01), muscle invasive (p < 0.05) and recurrent tumors (p < 0.01), while the c-erbB-2 gene product was more commonly detected in high-grade (p < 0.01), invasive (p < 0.01) and recurrent tumors (p < 0.05). Thus, the expression of either ras or c-erbB-2 was closely associated with the histological grade, clinical stage and recurrence of bladder transitional cell carcinomas.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8096102     DOI: 10.1007/bf00295190

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  25 in total

1.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

Review 2.  The molecular genetics of cancer.

Authors:  J M Bishop
Journal:  Science       Date:  1987-01-16       Impact factor: 47.728

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Expression of the c-erbB-2 protein in normal and transformed cells.

Authors:  W J Gullick; M S Berger; P L Bennett; J B Rothbard; M D Waterfield
Journal:  Int J Cancer       Date:  1987-08-15       Impact factor: 7.396

5.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer.

Authors:  Y Yonemura; I Ninomiya; A Yamaguchi; S Fushida; H Kimura; S Ohoyama; I Miyazaki; Y Endou; M Tanaka; T Sasaki
Journal:  Cancer Res       Date:  1991-02-01       Impact factor: 12.701

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

Review 8.  Oncogenes and onco-suppressor genes: their involvement in cancer.

Authors:  D A Spandidos; M L Anderson
Journal:  J Pathol       Date:  1989-01       Impact factor: 7.996

9.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.

Authors:  M F Press; C Cordon-Cardo; D J Slamon
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

10.  ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma.

Authors:  M V Viola; F Fromowitz; S Oravez; S Deb; J Schlom
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  4 in total

1.  Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis.

Authors:  Lan Mo; Xiaoyong Zheng; Hong-Ying Huang; Ellen Shapiro; Herbert Lepor; Carlos Cordon-Cardo; Tung-Tien Sun; Xue-Ru Wu
Journal:  J Clin Invest       Date:  2007-01-25       Impact factor: 14.808

Review 2.  Molecular biology of dissemination in bladder cancer--laboratory findings and clinical significance.

Authors:  B J Schmitz-Dräger; F Jankevicius; R Ackermann
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

3.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

4.  Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma.

Authors:  Gonzague de Pinieux; Delphine Colin; Anne Vincent-Salomon; Jérôme Couturier; Delphine Amsellem-Ouazana; Philippe Beuzeboc; Annick Vieillefond
Journal:  Virchows Arch       Date:  2004-03-17       Impact factor: 4.064

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.